Boston Scientific shares are trading lower after the company announced data from its HI-PEITHO clinical trial evaluating the EKOS Endovascular System in patients with pulmonary embolism. EKOS demonstrated a 61% reduction in primary endpoint events. Also, Raymond James downgraded its rating on the stock from Strong Buy to Outperform and lowered its price target from $97 to $88.